Sarah Glover
Family · Richland, WANPI 1962091652
Payments from drug & device makers
Across 87 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$709
- AstraZeneca$572
- Novo Nordisk$162
- Bayer$112
- Daiichi Sankyo Inc.$103
- Otsuka America Pharmaceutical, Inc.$60
- plus $317 from 13 others
What the payments were for
- Food & beverage$2,036100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $709 |
| AstraZeneca | 17 | $572 |
| Novo Nordisk | 8 | $162 |
| Bayer | 6 | $112 |
| Daiichi Sankyo Inc. | 4 | $103 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Lilly USA, LLC | 3 | $58 |
| Pfizer | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 1 | $27 |
| Ironshore Pharmaceuticals Inc. | 1 | $25 |
| Viatris Specialty LLC | 1 | $21 |
| GSK | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Mylan Specialty L.p. | 1 | $16 |
| Organon | 2 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,036 in reported general payments places this provider in the 85th percentile of 1,706 family providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 21 | $21,509 |
| Xigduo XrDapaglifloz Propaned/Metformin | 20 | $19,309 |
| RybelsusSemaglutide | 15 | $16,074 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $9,658 |
| JardianceEmpagliflozin | 14 | $8,721 |
| MyrbetriqMirabegron | 13 | $5,520 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $867 |
| Atorvastatin Calcium | 115 | $724 |
| Metoprolol Succinate | 63 | $655 |
| Omeprazole | 32 | $614 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $488 |
| Estradiol | 12 | $448 |
| Lisinopril | 41 | $433 |
| Nifedipine ErNifedipine | 20 | $415 |
| Simvastatin | 19 | $386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $162 | $37,58336 claims |
| AstraZenecaBreztri Aerosphere | $572 | $9,65816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,706 family providers in Washington.
Other family in Richland
- Tracy Candace DegensteinRichland$11K
- Christina RodriguezRichland$9K
- Shawna PennyRichland$6K
- Patric SchineCentralia$842K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.